TSH Biopharm awarded for the 16th National Innovation Prize in Entrepreneur Category
2019.12.6
TSH Biopharm announced today (12/6) that ”The ctDNA and CTC Cancer Monitoring Liquid Biopsy Platform” is awarded for the 16th National Innovation Prize in Entrepreneur Category.
...
TSH Biopharm Submits New Drug Application to Taiwan FDA Seeking Approval of RNTA06 for the Treatment of Angina
2019.8.30
TSH Biopharm Submits New Drug Application to Taiwan FDA Seeking Approval of RNTA06 for the Treatment of Angina
...
TSH Biopharm working together with InnoPharmax and Shandong Newtime Pharmacutical enter into global agreement of
2019.7.8
TSH Biopharm working together with InnoPharmax and Shandong Newtime Pharmacutical enter into global agreement of
...
Taiwan Healthcare & Life Sciences Review 2019-Interview with Grace Yang, General Manager of TSH Biopharm
2019.7.18
Taiwan Healthcare & Life Sciences Review 2019-Interview with Grace Yang, General Manager of TSH Biopharm
...
The Bridging study of RNTA06, which is indicated for the treatment of chronic angina, is completed and unblended,
2019.6.26
The Bridging study of RNTA06, which is indicated for the treatment of chronic angina, is completed and unblended,
...
TSH Biopharm acquires the commercialization right of all CellMax Life liquid-biopsy diagnosis products
2019.2.13
TSH Biopharm acquires the commercialization right of all CellMax Life liquid-biopsy diagnosis products
...
